A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer

IRB/UVA Tracking #
20921
Contact
Maria Davenport
Contact Email
Contact Phone
1.434.297.4110
Phase
II
Primary purpose
Treatment
Cancer PI
Richard Hall
Status
OPEN TO ACCRUAL
Ages
Adult